Breaking News Instant updates and real-time market news.

CRME

Cardiome

$1.57

-0.03 (-1.88%)

07:08
03/20/18
03/20
07:08
03/20/18
07:08

Cipher to acquire Canadian business portfolio of Cardiome for C$25.5M

Cipher Pharmaceuticals and Cardiome Pharma announced their entry into a definitive arrangement agreement pursuant to which Cipher will acquire the Canadian business portfolio of Cardiome. The proposed transaction will be completed pursuant to the acquisition by Cipher of all of the outstanding shares of Cardiome, following a restructuring of Cardiome pursuant to a statutory plan of arrangement under the Canada Business Corporations Act. Pursuant to the arrangement, Cardiome shareholders will receive common shares, on a one-for-one ratio, of a newly created Canadian entity named Correvio Pharma Corp. that will apply for a substitution listing on the Nasdaq and TSX. Correvio will acquire and hold all of Cardiome's pre-transaction assets, excluding the Canadian business portfolio being acquired by Cipher under the arrangement. The proposed transaction will be completed by way of a statutory plan of arrangement under the Canada Business Corporations Act. Pursuant to the arrangement, among other steps and procedures, the following transactions will occur: All of the outstanding common shares of Cardiome will be assigned and transferred to Correvio in exchange for common shares of Correvio. Following the completion of the share exchange, each former shareholder of Cardiome will hold the same pro rata interest in Correvio as it held in Cardiome immediately prior to such share exchange. All of the assets and liabilities of Cardiome, other than the Canadian business portfolio to be acquired by Cipher, will be transferred to and assumed by Correvio. Cipher will subsequently acquire all of the outstanding common shares of Cardiome, which will then be 100% owned by Correvio and hold only the Canadian business portfolio, for cash consideration of C$25.5M. Cipher expects to finance this acquisition with a combination of cash and new debt. Under the terms of the arrangement agreement, Cipher will also have a right of first refusal, for a limited period following closing, to license from Correvio the Canadian rights of any pharmaceutical product that it (or its affiliates) licenses in the future for additional consideration to Correvio. The proposed arrangement will require the approval of at least 66 2/3 percent of the votes cast in person or by proxy by shareholders of Cardiome at a special meeting expected to be held on or about May 9, 2018. All of the directors and senior officers of Cardiome have entered into voting and support agreements with Cipher pursuant to which they have agreed, among other things, to vote in favour of the arrangement. In addition to the approvals required from shareholders of Cardiome and the Supreme Court of British Columbia, the arrangement is also subject to applicable regulatory approvals, including Nasdaq and TSX approval, and the satisfaction of certain other closing conditions customary for a transaction of this nature. The definitive arrangement agreement includes customary deal protections, including fiduciary-out provisions, non-solicitation covenants, and the right to match any superior proposals. Additionally, a termination fee of C$2.5M is payable by Cardiome to Cipher in certain circumstances, and a reverse termination fee of C$2.5M is payable by Cipher to Cardiome in certain circumstances, if the proposed arrangement is not completed.

CRME Cardiome
$1.57

-0.03 (-1.88%)

07/17/17
ADAM
07/17/17
INITIATION
Target $8
ADAM
Buy
Cardiome assumed with a Buy at Canaccord
Canaccord analyst Dewey Steadman assumed coverage on Cardiome with a Buy rating as he sees an attractive top-line growth story driven by a unique business model commercializing hospital-based assets outside the U.S. market. The analyst sees additional upside driven by potential future business development and progress on commercialization of Brinavess. Steadman has an $8 price target on Cardiome shares.
11/15/17
ADAM
11/15/17
NO CHANGE
Target $5
ADAM
Buy
Cardiome price target lowered to $5 from $8 at Canaccord
Canaccord analyst Dewy Steadman lowered his price target on Cardiome to $5 from $8 following Q3 results that came in light on revenues due to timing issues. The analyst said he is not concerned abut the near-term weakness but he lowered his long-term peak revenue expectations for several products. Steadman remains positive on the absolute growth potential in Cardiome's overlooked European markets and he reiterated his Buy rating on Cardiome shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.